DOCSLIB.ORG

Annual Meeting Posters and Abstracts 1989 (Pdf)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Meeting Posters and Abstracts 1989 (Pdf) PROGRAM AND PAPERS ON NEW RESEARCH IN SUMMARY FORM THE ONE HUNDRED AND FORTY-SECOND ANNUAL MEETING OF THE AMERICAN PSYCHIATRIC ASSOCIATION SAN FRANCISCO, CALIFORNIA May 6-11, 1989 Papers presented at New Research Sessions are not automatically the property of the American Journal of Psychiatry. Authors are free to submit them to the Ameri­ can Journal of Psychiatry, Hospital & Community Psychiatry, or another publication of their choice. SUBCOMMITTEE ON NEW RESEARCH OF THE SCIENTIFIC PROGRAM COMMITTEE Allan Tasman, M.D. Farmington, CT Charles A. Kaufmann, M.D. Peter S. Jensen, M.D. John Markowitz, M.D. New York, NY Fort Gordon, GA New York, NY John Morihisa, M.D. Susan Fiester, M.D. Arnold Werner, M.D. Washington, DC Nashua, NH East Lansing, MI Outside Reviewers for New Research Program Hagop S. Akiskal, M.D. Charles P. O'Brien, M.D. Nancy C. Andreasen, M.D. John M. Oldham, M.D. Jack D. Barchas, M.D. Davia Pickar, M.D. Wade H. Berrenttini, M.D. Robert M. Post, M.D. Richard L. Borison, M.D. William Z. Potter, M.D. Gabrielle A. Carlson, M.D. Joachim Puig-Antich, M.D. Joseph T. Coyle, M.D. Fred M. Quitkin, M.D. Raymond R. Crowe, M.D. Murray A. Raskind, M.D. Glen C. Davis, M.D. Stephen G. Rayport, M.D. Marshal F. Folstein, M.D. Elliott Richelson, M.D. Arnold J. Friedhoff, M.D. Peter P. Roy-Byrne, M.D. Abby J. Fyer, M.D. A. John Rush, M.D. Elliott S. Gershon, M.D. Michael H. Sacks, M.D. Ira D. Glick, M.D. Charles A. Shamoian, M.D. Judith H. Gold, M.D. Larry J. Siever, M.D. Jack M. Gorman, M.D. Jonathan M. Silver, M.D. Igor Grant, M.D. Andrew E. Skodol, M.D. Katherine A. Halmi, M.D. Robert L. Spitzer, M.D. Dilip V. Jeste, M.D. Michael J. Stanley, M.D. John. M. Kane, M.D. Marvin Stein, M.D. Frederick I. Kass, M.D. James J. Strain, M.D. Herbert D. Kleber, M.D. Trey Sunderland, M.D. Donald F. Klein, M.D. Kenneth J. Tardiff, M.D. Joel E. Kleinman, M.D. Gary J. Tucker, M.D. Donald S. Kornfeld, M.D. Joe P. Tupin, M.D. David J. Kupfer, M.D. Thomas W. Uhde, M.D. Michael D. Liebowitz, M.D. Fred Vokmar, M.D. Markku V. Linnoila, M.D. B. Timothy Walsh, M.D. Herbert V. Meltzer, M.D. Daniel R. Weinberger, M.D. John M. Morihisa, M.D. George E. Woody, M.D. Charles B. Nemeroff, M.D. Stuart C. Yudofsky, M.D. Monday, May 8, 1989, 9:00 a.m.-10:30 a.m. New Research 1-Poster Session-Yosemite Room, Ballroom Level, Hilton YOUNG INVESTIGATORS' POSTER SESSION Moderator: Harold Alan Pincus, M.D. NR1 Abuse and Self-Injury in Adolescent Inpatients Timothy G. Lesaca, M.D. NR2 Ventricle-Brain Ratio in Schizophrenia: Clinical Correlations John R. Dequardo, M.D., Raymond Kloss, M.D., Rajiv Tandon, M.D. NR3 Trait Anxiety and Psychomotor Activity Duncan Clark, M.D., Roy King, M.D., Jurgen Margraf, Ph.D., Walton T. Roth, M.D., Stewart Agras, M.D., C. Barr Taylor, M.D. NR4 Anticholinergics and Cardiac Function During ECT Shashidhar M. Shettar, M.D., Leon Grunhaus, M.D., Atul C. Pande, M.D., Rajiv Tandon, M.D., Ziad Kronfol, M.D. NR5 Relationship Between Sleep EEG Measures and ECT Seizure Length Shashidhar M. Shettar, M.D., James E. Shipley, M.D., Leon Grunhaus, M.D., Roger F. Haskett, M.D., Alan S. Eiser, Ph.D. NR6 Spread of Cocaine Among Adults and Adolescents John E. Hickey, L.C.S.W., Anne F. Kolar, M.D., Barry S. Michaelson, M.A., Anneke Chung, B.A., Carolyn Haynie, M.D., Barry S. Brown, Ph.D. NR7 Cocaine: Perceived, Risk and Sources of Information John E. Hickey, L.C.S.W., Barry S. Brown, Ph.D., Anne S. Chung, B.A., Anne F. Kilar, M.D., Barry S. Michaelson, M.A. NR8 Age and the Prevalence of Dissociation Robert W. Hermanowski, 8.S., Moshe S. Torem, M.D., Kathryn J. Curdue, M.D. NR9 Profile of Dropouts and Attenders in a Family Support Group Mary L. De Florio, M.D., Stephen A. Cole, M.D., Samuel Simmens, Ph.D., Robert Shapiro, Ph.D., Stuart Barr, M.D., Danny Wu, M.D. NR10 Negative Symptom Assessment in Schizophrenia Raman Sood, M.D., Rodney J. Pelchat, M.D., Larry D. Alphs, M.D., Jerome Levine, M.D., Harini Balu, M.D., Allen Raskin, Ph.D. NR11 Comparison of Negative Symptom Scale Jose de Leon, M.D., George M. Simpson, M.D., William H. Wilson, M.D. NR12 CCRT: A Method for Comparing Neurotics and Borderline Ellen K .. Schiefer, M.D., Michael A. Selzer, M.D., John Clarkin, Ph.D., Frank Yeomans, M.D., Lester Lubarsky, M.D. NR13 Serotonin Probes in Obsessive Compulsive Disorder Teresa A. Pigott, M.D., Dennis L. Murphy, M.D., Michele T. Pato, M.D., James L. Hill, Ph.D., Gay Grover, M.S.N., Chawki Benkelfat, M.D. 1 NR14 Clomipramine Versus Buspirone in OCD: A Controlled Trial Michele T. Pato, M.D., Teresa A. Pigott, M.D., James L. Hill, Ph.D., Gay Grover, M.S.N., Suzanne E. Bernstein, B.S., Dennis L. Murhpy, M.D. NR15 Somatostatin in Alzheimer's Disease Susan E. Molchan, M.D., David R. Rubinow, M.D., Brian A. Lawlor, M.D., Rick A. Martinez, M.D., James L. Hill, Ph.D., Alan M. Mellow, M.D., Trey Sunderland, M.D. NR16 The Impact of Locked Units on Seclusion Practices Michael J. Sedlacek, M.D., William J. Burke, M.D., Steven Wengel, M.D. NR17 The DST: Refinement of Predictive Value Scott B. Patten, M.D. NR18 Effect of Vasopressin and Naloxone on Cortisol E. Jane Garland, M.D., A. P. Zis, M.D. NR19 Metabolic Rates in OCD and Comprisons with Panic Disorders Thomas E. Nordahl, M.D., Chawki Benkelfat, M.D., William E. Semple, Ph.D., Murray B. Stein, M.D., Thomas A. Mellman, M.D., Michael Gross, M.D., Thomas W. Uhde, M.D., Robert M. Cohen, M.D. NR20 5-HT Function in the Biochemical Response to MCPP John P. Selbyl, M.D., Dennis S. Charney, M.D., John H. Krystal, M.D., Lawrence H. Price, M.D., George R. Heninger, M.D. NR21 Do Mast and Cage Scores Help Detect Alcoholism? Connie M. Marsh, M.D., Donna A. Vaughan, M.D. NR22 Long-Staying Inpatients: A Descriptive Study Terry M. Brown, D.O., Robert N. Golden, M.D., David Ekstrom, M.Ph., Helen L. Miller, M.D., Dwight L. Evans, M.D. NR23 Cognitive Impairment in Tardive Dyskinesia Michael F. Egan, M.D., James Gold, Ph.D., Terry Goldberg, Ph.D., Darrell G. Kirch, M.D., David G. Daniel, M.D., Richard Jed Wyatt, M.D., Daniel R. Weinberger, M.D. NR24 DSPECT in Obsessive Compulsive Disorder John R. Debus, M.D., Michael D. Devous, Ph.D., John W. Cain, M.D., John Battaglia, M.D., S. Nadeem Ahmed, M.D., A. John Rush, M.D. NR25 Effect of Weight Loss on Brain Neuropeptide mRNAs Mark A. Smith, M.D., Linda S. Brady, Ph.D., Philip W. Gold, M.D. NR26 Psychiatry Resident Identification in a Strike Robert Kohn, M.D., Ronald M. Wintrob, M.D. NR27 Anti-HLA Antibodies and Chlorpromazine Robert C. Alexander, M.D., Mark A. Coggiano, M.S., Richard Jed Wyatt, M.D. NR28 Brain Structure and Function in Schizophrenia Ana Maria Andia, M.D., Julie Kuck, M.A. NR29 Ventricular Brain Ratios in Dementia: Depression and Controls Rick A. Martinez, M.D., Susan E. Molchan, M.D.,James L. Hill, Ph.D., Brian A. Lawlor, M.D., David Rubinow, M.D., Trey Sunderland, M.D. NR30 Stimulant/Haldol Study of SPEM CPT and P50 in Normals Dolores Malaspina, M.D., Edward Maclin, Ph.D., Barbara Cornblatt, Ph.D., Eliza A. Coleman, B.A, Harold Sackeim, Ph.D.,. Charles A. Kaufmann, M.D. 2 NR31 Substance Abuse in Borderline Personality Disorder Rebecca A. Dulit, M.D., Minna Fyer, M.D., Timothy Sullivan, M.D., Allen J. Frances, M.D. NR32 AIDS Knowledge and Attitudes in Psychiatric Staff Carol L. Alter, M.D., Gregory Miller, M.D., Ellen Dickinson, M.D. NR33 Effects of Different Light Wavelengths in SAD Dan A. Oren, M.D., George C. Brainard, Ph.D., Jean R. Joseph-Vanderpool, M.D., Elizabeth Sorek, R.N., Scott Johnston, B.A., Norman E. Rosenthal, M.D. NR34 Deep White Matter Hyperintensity on MRI Raymond F. Deicken, M.D., Victor I. Reus, M.D., Luisa Manfredi, B.A., Owen M. Wolkowitz, M.D. NR35 Changes in Cerebral Laterality with the Menstrual Cycle Margaret Altemus, M.D., Bruce Wexler, M.D., Glenna King, B.A. NR36 Comparison of Symptoms in OCD and Tourette's Kathy J. Tobias-Smith, M.D., David L. Pauls, Ph.D. NR37 Structural Changes in Astrocytes in an Experimental Model of Temporal Lobe Epilepsy Aldo Joseph Castiglioni Jr., M.D., Steve Peterson, Ph.D., Evelyn Tiffany-Castiglioni, Ph.D. NR38 Alcoholism and CSF IgG Synthesis in HIV Seropositive Men Karen P.G. Drexler, M.D., James Rundell, M.D., George Brown, M.D., Susan Paolucci, M.D., Joseph Pace, M.D., Susan McManis, M.D. NR39 Irritability and Apathy in Huntington's Disease Carol E. Peyser, M.D., Marshal F. Folstein, M.D., Sergio E. Starkstein, M.D., Susan E. Folstein, M.D. NR40 Fluoxetine Induced Mania David E. Hon, M.D., Sheldon H. Preskorn, M.D. NR41 Abuse, Dissociation and PTSD in LLPDD Patients Margaret F.
Load more

Recommended publications
  • Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A
    1 Background to the Celebration of Herbert D. Kleber (1904 -2018) by Thomas A. Ban By the mid-1990s the pioneering generation in neuropsychopharmacology was fading away. To preserve their legacy the late Oakley Ray (1931-2007), at the time Secretary of the American College of Neuropsychopharmacology (ACNP), generated funds from Solway Pharmaceuticals for the founding of the ACNP-Solway Archives in Neuropsychopharmacology. Ray also arranged for the videotaping of interviews (mainly by their peers) with the pioneers, mostly at annual meetings, to be stored in the archives. Herbert Kleber was interviewed by Andrea Tone, a medical historian at the Annual Meeting of the College held in San Juan, Puerto Rico, on December 7, 2003 (Ban 2011a; Kleber 2011a). The endeavor that was to become known as the “oral history project” is based on 235 videotaped interviews conducted by 66 interviewers with 213 interviewees which, on the basis of their content, were divided and edited into a 10-volume series produced by Thomas A. Ban, in collaboration with nine colleagues who were to become volume editors. One of them, Herbert Kleber, was responsible for the editing of Volume Six, dedicated to Addiction (Kleber 2011b). The series was published by the ACNP with the title “An Oral History of Neuropsychopharmacology Peer Interviews The First Fifty Years” and released at the 50th Anniversary Meeting of the College in 2011 (Ban 2011b). Herbert Daniel Kleber was born January 19, 1934, in Pittsburgh, Pennsylvania. His family’s father’s side was from Vilnius, Lithuania, and the Mother’s side was from Germany. Both families came to the United State during the first decade of the 20th century.
    [Show full text]
  • The Dopamine Transporter: More Exciting Than Housekeeping
    The Dopamine Transporter: More Exciting than Housekeeping Susan Ingram Washington State University Vancouver Dopaminergic Synapse Presynaptic cell MGluR 2 Na+ Cl- GIRK D2 DA DA D2 D1 a1 Postsynaptic cell Currents are activated at lower dopamine concentrations than are required for transport Ingram, et al., 2002 Low DA concentrations increase firing Ingram, et al., 2002 DAT-mediated chloride current is excitatory in cultured midbrain DA neurons DEPOLARIZATION HYPERPOLARIZATION Ingram, et al., 2002 Proteins that regulate intracellular Cl- Whole-cell patch clamp recordings from DA neurons Raclopride Sulpiride Prazosin TTX biocytin Prasad and Amara, 2001 Amphetamine activates a DAT-mediated current at low concentrations Cultures Slices Watts, Fyfe and Ingram, unpublished data. DA neurons make glutamatergic autapses in culture and amphetamine increases AMPA currents Ingram, et al., unpublished data mbYFPQS localizes to the membrane of cultured midbrain neurons Watts, Jimenez and Ingram, unpublished data. Amphetamine stimulates a dose-dependent change in mbYFPQS fluorescence in both soma and dendrites of DA neurons Watts and Ingram, unpublished data. KCC2 Expression is different in cultures and slices cultures slices TH KCC2 Jamieson and Ingram, unpublished data. Baculoviral Transfections Watts and Ingram, unpublished data. Summary • DAT-mediated chloride current may alter excitability of DA neurons and integration of synaptic activity. • The current may be activated selectively (relative to transport) by low DA and amphetamine concentrations suggesting a role in increasing release of DA. • The amphetamine-mediated current is dose-dependent in both cultures and slices of midbrain neurons but is inhibited at high amphetamine concentrations (20 µM). • The mbYFPQS is a sensitive tool to measure intracellular chloride concentrations (K50 = 30 mM) and is useful for monitoring changes in intracellular chloride concentrations in dendrites.
    [Show full text]
  • Program Book
    PARKINSON’SDISEASE2014 ADVANCING RESEARCH, IMPROVING LIVES PROGRAM MATERIALS Sponsored by: January 6 – 7, 2014 Natcher Conference Center National Institutes of Health Bethesda, MD About our cover: The program cover image is a stylized version of the Parkinson’s Disease Motor-Related Pattern (PDRP), an abnormal pattern of regional brain function observed in MRI studies which shows increased metabolism indicated by red in some brain regions (pallidothalamic, pontine, and motor cortical areas), and decreased metabolism indicated by blue in others (associated lateral premotor and posterior parietal areas). Original image used with permission of David Eidelberg, M.D. For further information see: Hirano et al., Journal of Neuroscience 28 (16): 4201-4209. Welcome Message from Dr. Story C. Landis Welcome to the National Institute of Neurological Disorders and Stroke (NINDS) conference, “Parkinson’s Disease 2014: Advancing Research, Improving Lives.” Remarkable new discoveries and technological advances are rapidly changing the way we study the biological mechanisms of Parkinson’s disease, identify paths to improved treatments, and design effective clinical trials. Elucidating mechanisms and developing and testing effective interventions require a diverse set of approaches and perspectives. The NINDS has organized this conference with the primary goal of seeking consensus on, and prioritizing, research recommendations spanning clinical, translational, and basic Parkinson’s disease research that we support. We have assembled a stellar and dedicated group of session chairs and panelists who have worked collaboratively to identify emerging research opportunities in Parkinson’s research. While we have divided our working groups into three main research areas, we expect each will inform the others over the course of the next two days, and we look forward to both complementary and unique perspectives.
    [Show full text]
  • Isoflurane Inhibits Dopaminergic Synaptic Vesicle Exocytosis Coupled to Cav2.1 and Cav2.2 in Rat Midbrain Neurons
    This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. Research Article: New Research | Neuronal Excitability Isoflurane inhibits dopaminergic synaptic vesicle exocytosis coupled to CaV2.1 and CaV2.2 in rat midbrain neurons Christina L. Torturo1,2, Zhen-Yu Zhou1, Timothy A. Ryan1,3 and Hugh C. Hemmings1,2 1Departments of Anesthesiology, Weill Cornell Medicine, New York, NY 10065 2Pharmacology, Weill Cornell Medicine, New York, NY 10065 3Biochemistry, Weill Cornell Medicine, New York, NY 10065 https://doi.org/10.1523/ENEURO.0278-18.2018 Received: 16 July 2018 Revised: 18 December 2018 Accepted: 21 December 2018 Published: 10 January 2019 Author Contributions: CLT, ZZ, TAR and HCH designed the research; CLT performed the research, TAR contributed unpublished reagents/analytic tools; CLT and ZZ analyzed the data; CLT, ZZ, TAR, and HCH wrote the paper. Funding: http://doi.org/10.13039/100000002HHS | National Institutes of Health (NIH) GM58055 Conflict of Interest: HCH: Editor-in-Chief of the British Journal of Anaesthesia; consultant for Elsevier. Funding Sources: NIH GM58055 Corresponding author: Hugh C. Hemmings, E-mail: [email protected] Cite as: eNeuro 2019; 10.1523/ENEURO.0278-18.2018 Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process. Copyright © 2019 Torturo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.
    [Show full text]
  • Conference Schedule
    Society on NeuroImmune Pharmacology (SNIP) 23rd Scientific Conference Hotel DOUBLETREE BY HILTON PHILADELPHIA CENTER CITY Philadelphia, PA, USA March 29 - April 1, 2017 Previous Conferences:1993 Toronto Hilton, Canada; 1994 Breakers, Palm Beach, FL; 1995 Bristol Court, San Diego, CA; 1996 Caribe Hilton, San Juan, PR; 1997 Opryland Hotel, Nashville TN; 1998 Scottsdale Princess, Scottsdale, AR; 2000 NIH Mazur Auditorium, Bethesda MD; 2001 Emory University, Atlanta, GA; 2002 Clearwater Beach Hilton, Clear Water, FL; 2004, La Fonda Hotel, Santa Fe, NM; 2005 Clearwater Beach Hilton, Clear Water, FL; 2006 La Fonda Hotel, Santa Fe, NM; 2007 City Center Marriott Hotel, Salt Lake City, UT; 2008 Francis Marion Hotel, Charleston, SC; 2009 Pearl Plaza Howard Johnson, Wuhan, China; 2010 Manhattan Beach Marriott, Manhattan Beach, CA; 2011 Hilton Clearwater Beach Resort, Clear Water Beach, FL; 2012 Hawaii Prince Hotel, Honolulu, HI; 2013 Conrad Hilton, San Juan, PR; 2014 Intercontinental New Orleans, LA.; 2015; Hyatt Regency, Miami, FL; 2016, Hotel Galaxy, Krakow, Poland. Page 1 TABLE OF CONTENTS Title Page 1 Table of Contents 2 Acknowledgement of Special Contributors and Sponsors 3-5 The SNIP Council, Officials, and Committees 6-7 Annual Society Awards 8-9 2016 Early Career Investigator Travel Awardees 9-11 2016 Plenary Speaker Biographies 12-14 Conference Agenda Wednesday March 29, 2017 City-Wide NeuroAIDS Discussion Group 15-16 Opening Reception 16 Poster Session 1 (W1-72, Abstract listings page 25) 16 1st Annual DISC Networking Hour 16 Thursday March 30, 2017 Presidential Symposium: Dopamine Neurotransmission in HIV-1 Infection 16-17 Presidential Symposium: Dr. David Sulzer 17 Symposium 2: Novel mechanisms of CNS infection 17-18 Meet the Mentors Lunch 18 SNIP Council Meeting 18 Pharmacology Symposium: Dr.
    [Show full text]
  • Fall 2014 Columbia Magazine Collaborations 45 Startups
    FALL 2014 COLUMBIA MAGAZINE COLLABORATIONS 45 STARTUPS. 1 GARAGE. C1_FrontCover_v1.indd C1 10/1/14 4:41 PM ChangeCHANGETHEWORLD lives, On October 29, join Columbians around the globe for 24 hours of giving back, connecting, and chances to win matching funds for your favorite school or program. Changing Lives That Change The World givingday.columbia.edu #ColumbiaGivingDay C2_GivingDay.indd C2 9/30/14 5:45 PM CONTENTS Fall 2014 12 44 26 DEPARTMENTS FEATURES 3 Letters 12 Start Me Up By Rebecca Shapiro 6 Primary Sources The new Columbia Startup Lab in SoHo is open Darwin in plain English . Gail Sheehy’s New York for business. We visit some young entrepreneurs to memories . Eric Holder goes to Ferguson see what clicks. 8 College Walk 22 Streams and Echoes Grab your coat and get your stethoscope . By Tim Page Decanterbury tales . Kenneth Waltz: The composer Chou Wen-chung, featured this fall as one A remembrance of the Miller Theatre’s “Composer Portraits,” has been connecting East and West for more than sixty years. 48 News Amale Andraos named dean of GSAPP . 26 The Professor’s Last Stand Columbia gives seed grants to overseas research By David J. Craig projects . Brown Institute for Media Innovation US historian Eric Foner is trying something new before opens its doors . Columbia Secondary School he retires: he’s fi lming a massive open online course, graduates its fi rst class . David Goldstein or MOOC. Call it a Lincoln login. recruited to head new genomics institute . Bollinger’s term extended 34 Rewired By Paul Hond 53 Newsmakers Law professor Tim Wu, the coiner of “net neutrality,” entered New York’s lieutenant-governor race to change 55 Explorations politics.
    [Show full text]
  • HEHS-96-80 Cocaine Treatment Outcomes B-265688
    United States General Accounting Office GAO Report to Congressional Requesters June 1996 COCAINE TREATMENT Early Results From Various Approaches GOA years 1921 - 1996 GAO/HEHS-96-80 United States General Accounting Office GAO Washington, D.C. 20548 Health, Education, and Human Services Division B-265688 June 7, 1996 The Honorable William F. Clinger, Jr. Chairman The Honorable Cardiss Collins Ranking Minority Member Committee on Government Reform and Oversight House of Representatives The Honorable Henry A. Waxman House of Representatives Cocaine use in the United States remains a serious and costly epidemic. In 1994, the National Household Survey on Drug Abuse conservatively estimated that more than three-quarters of a million people had used cocaine at least once a week within the past year. In 1993, cocaine was associated with almost 4,000 deaths.1 Today, an estimated $10 billion per year is lost in cocaine-related crimes and productivity.2 Although cocaine admissions to state-supported drug abuse treatment programs between 1985 and 1990 increased dramatically—from almost 39,000 people to more than 200,000—we found in 1991 that an effective treatment for cocaine addiction had not yet been identified.3 Today, public/private expenditures on cocaine-related treatment total about $1 billion per year. Because of cocaine’s serious health, economic, and criminal justice implications for the nation, we have provided a status report on recent progress made in finding an effective treatment for cocaine users.4 Specifically, we reviewed the various types of federally funded treatment approaches evaluated over the past 5 years (1991 through 1995) to (1) determine the extent to which these therapies have proven successful and (2) identify additional research initiatives necessary to increase our knowledge of cocaine treatment effectiveness.
    [Show full text]
  • Development of a Lab-On-A-Chip Device for Rapid Nanotoxicity Assessment in Vitro Pratikkumar Shah Engineering, [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 12-11-2014 Development of a Lab-on-a-Chip Device for Rapid Nanotoxicity Assessment In Vitro Pratikkumar Shah Engineering, [email protected] DOI: 10.25148/etd.FI15032160 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Analytical Chemistry Commons, Bioelectrical and Neuroengineering Commons, Biomedical Devices and Instrumentation Commons, Electronic Devices and Semiconductor Manufacturing Commons, Molecular, Cellular, and Tissue Engineering Commons, and the Nanotechnology Fabrication Commons Recommended Citation Shah, Pratikkumar, "Development of a Lab-on-a-Chip Device for Rapid Nanotoxicity Assessment In Vitro" (2014). FIU Electronic Theses and Dissertations. 1834. https://digitalcommons.fiu.edu/etd/1834 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida DEVELOPMENT OF A LAB-ON-A-CHIP DEVICE FOR RAPID NANOTOXICITY ASSESSMENT IN VITRO A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in BIOMEDICAL ENGINEERING by Pratikkumar Shah 2015 To: Dean Amir Mirmiran College of Engineering and Computing This dissertation, written by Pratikkumar Shah, and entitled Development of a Lab-on-a- Chip Device for Rapid Nanotoxicity Assessment In Vitro, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved.
    [Show full text]
  • Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis
    The Journal of Neuroscience, October 15, 2002, 22(20):8951–8960 Methamphetamine-Induced Degeneration of Dopaminergic Neurons Involves Autophagy and Upregulation of Dopamine Synthesis Kristin E. Larsen,1 Edward A. Fon,2 Teresa G. Hastings,3 Robert H. Edwards,4 and David Sulzer1 1Departments of Neurology and Psychiatry, Columbia University, and Department of Neuroscience, New York Psychiatric Institute, New York, New York 10032, 2Centre for Neuronal Survival, Montreal Neurological Institute, McGill University, Montreal, Quebec H3A 2B4, Canada, 3Departments of Neuroscience and Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261, and 4Departments of Neurology and Physiology, University of California, San Francisco, California 94143 Methamphetamine (METH) selectively injures the neurites of pression. METH administration also promoted the synthesis of dopamine (DA) neurons, generally without inducing cell death. It DA via upregulation of tyrosine hydroxylase activity, resulting in has been proposed that METH-induced redistribution of DA an elevation of cytosolic DA even in the absence of vesicular from the vesicular storage pool to the cytoplasm, where DA can sequestration. Electron microscopy and fluorescent labeling oxidize to produce quinones and additional reactive oxygen confirmed that METH promoted the formation of autophagic species, may account for this selective neurotoxicity. To test granules, particularly in neuronal varicosities and, ultimately, this hypothesis, we used mice heterozygous (ϩ/Ϫ) or homozy- within cell bodies of dopaminergic neurons. Therefore, we pro- gous (Ϫ/Ϫ) for the brain vesicular monoamine uptake trans- pose that METH neurotoxicity results from the induction of a porter VMAT2, which mediates the accumulation of cytosolic specific cellular pathway that is activated when DA cannot be DA into synaptic vesicles.
    [Show full text]
  • Mens Rea and Methamphetamine: High Time for a Modern Doctrine Acknowledging the Neuroscience of Addiction
    Fordham Law Review Volume 85 Issue 5 Article 20 2017 Mens Rea and Methamphetamine: High Time for a Modern Doctrine Acknowledging the Neuroscience of Addiction Meredith Cusick Fordham University School of Law Follow this and additional works at: https://ir.lawnet.fordham.edu/flr Part of the Criminal Law Commons Recommended Citation Meredith Cusick, Mens Rea and Methamphetamine: High Time for a Modern Doctrine Acknowledging the Neuroscience of Addiction, 85 Fordham L. Rev. 2417 (2017). Available at: https://ir.lawnet.fordham.edu/flr/vol85/iss5/20 This Note is brought to you for free and open access by FLASH: The Fordham Law Archive of Scholarship and History. It has been accepted for inclusion in Fordham Law Review by an authorized editor of FLASH: The Fordham Law Archive of Scholarship and History. For more information, please contact [email protected]. MENS REA AND METHAMPHETAMINE: HIGH TIME FOR A MODERN DOCTRINE ACKNOWLEDGING THE NEUROSCIENCE OF ADDICTION Meredith Cusick* In American criminal law, actus non facit reum, nisi mens sit rea, “an act does not make one guilty, without a guilty mind.” Both actus reus and mens rea are required to justify criminal liability. The Model Penal Code’s (MPC) section on culpability has been especially influential on mens rea analysis. An issue of increasing importance in this realm arises when an offensive act is committed while the actor is under the influence of drugs. Several legal doctrines address the effect of intoxication on mental state, including the MPC, limiting or eliminating its relevance to the mens rea analysis. Yet these doctrines do not differentiate between intoxication and addiction.
    [Show full text]
  • Arxiv:2107.12536V2 [Q-Bio.NC] 1 Sep 2021
    ADATA-DRIVEN BIOPHYSICAL COMPUTATIONAL MODEL OF PARKINSON’S DISEASE BASED ON MARMOSET MONKEYS Caetano M. Ranieri Jhielson M. Pimentel Institute of Mathematical and Computer Sciences Edinburgh Centre for Robotics University of Sao Paulo Heriot-Watt University Sao Carlos, SP, Brazil Edinburgh, Scotland, UK [email protected] [email protected] Marcelo R. Romano Leonardo A. Elias School of Electrical and Computer Engineering School of Electrical and Computer Engineering University of Campinas University of Campinas Campinas, SP, Brazil Campinas, SP, Brazil [email protected] [email protected] Roseli A. F. Romero Michael A. Lones Institute of Mathematical and Computer Sciences Edinburgh Centre for Robotics University of Sao Paulo Heriot-Watt University Sao Carlos, SP, Brazil Edinburgh, Scotland, UK [email protected] [email protected] Mariana F. P. Araujo Patricia A. Vargas Health Sciences Centre Edinburgh Centre for Robotics Federal University of Espirito Santo Heriot-Watt University Vitoria, ES, Brazil Edinburgh, Scotland, UK [email protected] [email protected] Renan C. Moioli Digital Metropolis Institute Federal University of Rio Grande do Norte Natal, RN, Brazil [email protected] September 2, 2021 arXiv:2107.12536v2 [q-bio.NC] 1 Sep 2021 ABSTRACT In this work we propose a new biophysical computational model of brain regions relevant to Parkin- son’s Disease (PD) based on local field potential data collected from the brain of marmoset monkeys. Parkinson’s disease is a neurodegenerative disorder, linked to the death of dopaminergic neurons at the substantia nigra pars compacta, which affects the normal dynamics of the basal ganglia-thalamus- cortex (BG-T-C) neuronal circuit of the brain.
    [Show full text]
  • CV Levin.Pdf
    CURRICULUM VITAE NAME: Frances Rudnick Levin, M.D. CURRENT POSITION: Kennedy-Leavy Professor of Psychiatry at Columbia University Medical Center Associate Attending of Psychiatry New York Presbyterian Hospital Chief, Division on Substance Abuse at Columbia University/New York State Psychiatric Institute (NYSPI) WORK ADDRESS: NYSPI/Department of Psychiatry 1051 Riverside Drive, Unit 66 New York, NY 10032 Telephone: 212-543-5896 HOME ADDRESS: 640 Pomander Walk Teaneck, NJ 07666 Telephone: 201-836-4219 PLACE OF BIRTH: Newton, MA MARITAL STATUS: Married - Howard Robert Levin, M.D. Founder, Coridea, Inc Founder, Cibiem, Inc. CHILDREN: Allison Paula, October 11, 1991 Tamara Stephanie, March 31, 1995 Charles Jacob, March 31, 1995 EDUCATION: 1974-1977 Newton South High School Newton, MA 1977-1981 Brown University Providence, RI B.S. - Magna Cum Laude with Honors 1981-1985 Cornell University Medical College New York, NY M.D. 1985-1989 Resident in Psychiatry The New York Hospital, Payne Whitney Clinic New York, NY 1988-1989 The New York Hospital, Payne Whitney Clinic New York, NY Assistant Unit Chief 1 1989-1990 National Institute on Drug Abuse and University of Maryland Baltimore, MD Research and Addiction Psychiatry Fellow ACADEMIC APPOINTMENTS: University of Maryland Medical Center, Department of Psychiatry 1990-1992 Assistant Professor Columbia University College of Physicians and Surgeons, Department of Psychiatry 1992-1999 Assistant Professor of Clinical Psychiatry 1999- 2006 Q.J. Kennedy Associate Professor of Clinical Psychiatry 2006-2013
    [Show full text]